Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6091820 | 0.99 | CCR5 (0.83) | CCR5KCNH2 | |
| Hydrochloric Acid SCHEMBL6091817 | 0.99 | CCR5 (0.83) | CCR5KCNH2 | |
| SCHEMBL12207016 | 0.92 | CCR5 (1.00) | CCR5 | |
| SCHEMBL6699455 | 0.91 | CCR5 (0.84) | CCR5 | |
| SCHEMBL6336926 | 0.91 | CCR5 (1.00) | CCR5 | |
| SCHEMBL6339869 | 0.91 | CCR5 (1.00) | CCR5 | |
| SCHEMBL14468466 | 0.90 | CCR5 (0.86) | CCR5KCNH2 | |
| SCHEMBL5439461 | 0.90 | CCR5 (0.86) | CCR5KCNH2 | |
| SCHEMBL5445929 | 0.90 | CCR5 (0.86) | CCR5KCNH2 | |
| SCHEMBL6367798 | 0.90 | CCR5 (0.82) | CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167048-A1 | N-4-piperidinyl compounds as ccr5 modulators | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| EP-1539695-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040266823-A1 | Novel piperidine derivatives as modulators of chemokine receptors | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
| EP-1448525-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | AstraZeneca AB (SE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004018425-A1 | N-4-PIPERIDINYL COMPOUNDS AS CCR5 MODULATORS | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003042178-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167048-A1 | N-4-piperidinyl compounds as ccr5 modulators | CCR5, CCL5, CCR2 | CCR5 1/4885KCNH2 2731/4885 |
| US-20040266823-A1 | Novel piperidine derivatives as modulators of chemokine receptors | CCR5, CCR2, CX3CR1 | CCR5 1/4885KCNH2 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.